Base de dados : MEDLINE
Pesquisa : C11.768.585.439 [Categoria DeCS]
Referências encontradas : 13114 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1312 ir para página                         

  1 / 13114 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471100
[Au] Autor:Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
[Ad] Endereço:Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea.
[Ti] Título:Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
[So] Source:Korean J Ophthalmol;31(3):240-248, 2017 Jun.
[Is] ISSN:2092-9382
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the 12-month outcome of intravitreal anti-vascular endothelial growth factor therapy in eyes with bilateral retinal angiomatous proliferation (RAP). METHODS: This retrospective observational study included 38 eyes of 19 patients with stage 1 or 2 bilateral RAP at diagnosis. The eyes of patients who exhibited different baseline best-corrected visual acuity (BCVA) values in both eyes were assigned to one of two groups-the better (n=13) and worse (n=13) visual acuity groups. The BCVA values in both groups were compared to those at baseline and at 12 months. In addition, the 12-month changes in BCVA were compared between the two groups. The association between the optical coherence tomography findings at diagnosis and the 12-month BCVA was also analyzed. RESULTS: The values of mean baseline and 12-month BCVA in the better visual acuity group (13 eyes) were 0.48 ± 0.19 and 0.58 ± 0.29, respectively, and those in the worse visual acuity group (13 eyes) were 0.83 ± 0.20 and 0.90 ± 0.31. The 12-month changes in BCVA were not significantly different between the two groups (p=0.786). Among the six patients with equivalent baseline BCVA in both eyes, four patients (66.7%) exhibited 1 to 2 lines or ≥3 lines of difference in BCVA between eyes at 12 months. Eyes without pigment epithelial detachment (PED) at diagnosis exhibited significantly better BCVA at 12 months than eyes with PED (p=0.021). CONCLUSIONS: Better baseline visual acuity was associated with better BCVA at 12 months posttreatment in patients with bilateral RAP. However, equivalent baseline visual acuity in both eyes might not guarantee similar treatment outcomes. In addition, the absence of PED is predictive of better visual outcome.
[Mh] Termos MeSH primário: Bevacizumab/administração & dosagem
Neovascularização de Coroide/tratamento farmacológico
Degeneração Macular/tratamento farmacológico
Ranibizumab/administração & dosagem
Acuidade Visual
[Mh] Termos MeSH secundário: Idoso
Inibidores da Angiogênese/administração & dosagem
Neovascularização de Coroide/diagnóstico
Feminino
Angiofluoresceinografia
Seguimentos
Fundo de Olho
Seres Humanos
Injeções Intravítreas
Degeneração Macular/diagnóstico
Masculino
Epitélio Pigmentado da Retina
Estudos Retrospectivos
Fatores de Tempo
Tomografia de Coerência Óptica
Resultado do Tratamento
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Vascular Endothelial Growth Factor A); 2S9ZZM9Q9V (Bevacizumab); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.3341/kjo.2016.0026


  2 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29368595
[Au] Autor:Park J; Lee M
[Ad] Endereço:Department of Ophthalmology, College of Medicine, Dankook University, 119, Dandae-ro, Dnognam-gu, Cheonan-si, Chungchungnam-do, Republic of Korea.
[Ti] Título:Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
[So] Source:BMC Ophthalmol;18(1):17, 2018 Jan 25.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study is to evaluate short-term effects and safety of an acute increase of intraocular pressure (IOP) after single-dose intravitreal bevacizumab injection on corneal endothelial cells and central corneal thickness. METHODS: Forty-two patients who underwent intravitreal injection of 2.5 mg/0.1 ml bevacizumab because of central serous chorioretinopathy or diabetic macular edema were included in this study. The changes of IOP, corneal endothelial cells, and corneal thickness at baseline, 2 min, 5 min, and 30 min after injection were analyzed prospectively with a specular microscope. RESULTS: In all patients, the mean IOPs at baseline, 2 min, 5 min, and 30 min after injection were 11.48 ± 2.22 mmHg, 49.71 ± 10.73 mmHg, 37.64 ± 11.68 mmHg, and 14.88 ± 4.77 mmHg, respectively. These changes were significant (p < 0.01). In only one eye, IOP did not decrease to ≤30 mmHg even at 30 min after injection. According to changes in IOP with time, the coefficient of variation of the corneal endothelium significantly increased (p = 0.03), but cell density, hexagonality of the corneal endothelium, and central corneal thickness did not change (p = 0.79, 0.21, and 0.08, prospectively). One week after injection, there was no sign of inflammation or any other complications in all 42 eyes. CONCLUSIONS: After intravitreal injection, IOP rapidly increases, then decreases to the normal range in most eyes 30 min after injection and it is tolerable to corneal endothelium. TRIAL REGISTRATION: Clinical Research Information Service (CRiS), Republic of Korea, KCT0002645 . Retrospectively registered 9 January 2018.
[Mh] Termos MeSH primário: Bevacizumab/efeitos adversos
Epitélio Posterior/efeitos dos fármacos
Pressão Intraocular/efeitos dos fármacos
Degeneração Macular/tratamento farmacológico
Edema Macular/tratamento farmacológico
Hipertensão Ocular/induzido quimicamente
[Mh] Termos MeSH secundário: Doença Aguda
Inibidores da Angiogênese/administração & dosagem
Inibidores da Angiogênese/efeitos adversos
Bevacizumab/administração & dosagem
Epitélio Posterior/patologia
Feminino
Seguimentos
Seres Humanos
Incidência
Pressão Intraocular/fisiologia
Injeções Intravítreas
Degeneração Macular/diagnóstico
Edema Macular/diagnóstico
Masculino
Meia-Idade
Hipertensão Ocular/epidemiologia
Hipertensão Ocular/fisiopatologia
Estudos Prospectivos
República da Coreia/epidemiologia
Fatores de Tempo
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Vascular Endothelial Growth Factor A); 2S9ZZM9Q9V (Bevacizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0682-9


  3 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187360
[Au] Autor:Fell G
[Ad] Endereço:Town Hall, Sheffield S1 2HH, UK.
[Ti] Título:The NHS must act on bevacizumab, for patients' sake.
[So] Source:BMJ;359:j5427, 2017 11 29.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Angiogênese/economia
Bevacizumab/economia
Análise Custo-Benefício/legislação & jurisprudência
Degeneração Macular/tratamento farmacológico
Oftalmologistas/ética
Ranibizumab/farmacologia
Proteínas Recombinantes de Fusão/farmacologia
Medicina Estatal/legislação & jurisprudência
[Mh] Termos MeSH secundário: Inibidores da Angiogênese/farmacologia
Bevacizumab/farmacologia
Acesso aos Serviços de Saúde
Seres Humanos
Degeneração Macular/economia
Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
Reino Unido/epidemiologia
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Recombinant Fusion Proteins); 15C2VL427D (aflibercept); 2S9ZZM9Q9V (Bevacizumab); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5427


  4 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29184013
[Au] Autor:Mackenzie JW
[Ad] Endereço:Royal Berkshire Hospital, Reading RG1 5AN, UK.
[Ti] Título:Time to ask patients about drugs for macular degeneration.
[So] Source:BMJ;359:j5426, 2017 11 28.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Angiogênese/economia
Bevacizumab/economia
Degeneração Macular/tratamento farmacológico
Degeneração Macular Exsudativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores da Angiogênese/administração & dosagem
Inibidores da Angiogênese/uso terapêutico
Bevacizumab/administração & dosagem
Bevacizumab/uso terapêutico
Análise Custo-Benefício/legislação & jurisprudência
Seres Humanos
Injeções Intravítreas
Degeneração Macular/economia
Degeneração Macular Exsudativa/economia
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 2S9ZZM9Q9V (Bevacizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5426


  5 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771146
[Au] Autor:Sardell RJ; Nittala MG; Adams LD; Laux RA; Cooke Bailey JN; Fuzzell D; Fuzzell S; Reinhart-Mercer L; Caywood LJ; Horst V; Mackay T; Dana D; Sadda SR; Scott WK; Stambolian D; Haines JL; Pericak-Vance MA
[Ad] Endereço:John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida.
[Ti] Título:Heritability of Choroidal Thickness in the Amish.
[So] Source:Ophthalmology;123(12):2537-2544, 2016 12.
[Is] ISSN:1549-4713
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the heritability of choroidal thickness and its relationship to age-related macular degeneration (AMD). DESIGN: Cohort study. PARTICIPANTS: Six hundred eighty-nine individuals from Amish families with early or intermediate AMD. METHODS: Ocular coherence tomography was used to quantify choroidal thickness, and fundus photography was used to classify eyes into categories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system. Repeatability and heritability of choroidal thickness and its phenotypic and genetic correlations with the AMD phenotype (CARMS category) were estimated using a generalized linear mixed model (GLMM) approach that accounted for relatedness, repeated measures (left and right eyes), and the effects of age, gender, and refraction. MAIN OUTCOME MEASURES: Heritability of choroidal thickness and its phenotypic and genetic correlation with the AMD phenotype (CARMS category). RESULTS: Phenotypic correlation between choroidal thickness and CARMS category was moderate (Spearman's rank correlation, r = -0.24; n = 1313 eyes) and significant (GLMM posterior mean, -4.27; 95% credible interval [CI], -7.88 to -0.79; P = 0.02) after controlling for relatedness, age, gender, and refraction. Eyes with advanced AMD had thinner choroids than eyes without AMD (posterior mean, -73.8; 95% CI, -94.7 to -54.6; P < 0.001; n = 1178 eyes). Choroidal thickness was highly repeatable within individuals (repeatability, 0.78; 95% CI, 0.68 to 0.89) and moderately heritable (heritability, 0.40; 95% CI, 0.14 to 0.51), but did not show significant genetic correlation with CARMS category, although the effect size was moderate (genetic correlation, -0.18; 95% CI, -0.49 to 0.16). Choroidal thickness also varied with age, gender, and refraction. The CARMS category showed moderate heritability (heritability, 0.49; 95% CI, 0.26 to 0.72). CONCLUSIONS: We quantify the heritability of choroidal thickness for the first time, highlighting a heritable, quantitative trait that is measurable in all individuals regardless of AMD affection status, and moderately phenotypically correlated with AMD severity. Choroidal thickness therefore may capture variation not captured by the CARMS system. However, because the genetic correlation between choroidal thickness and AMD severity was not significant in our data set, genes associated with the 2 traits may not overlap substantially. Future studies should therefore test for genetic variation associated with choroidal thickness to determine the overlap in genetic basis with AMD.
[Mh] Termos MeSH primário: Amish/genética
Corioide/patologia
Característica Quantitativa Herdável
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Corioide/diagnóstico por imagem
Estudos de Coortes
Feminino
Seres Humanos
Degeneração Macular/genética
Masculino
Meia-Idade
Tamanho do Órgão/genética
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470643
[Au] Autor:Habibi I; Sfar I; Kort F; Bouraoui R; Chebil A; Limaiem R; Ayed S; Ben Abdallah T; El Matri L; Gorgi Y
[Ad] Endereço:Research Laboratory of renal Transplantation and Immunopathology (LR03SP01), University Tunis El Manar, Charles Nicolle Hospital, Tunis, Tunisia (Chairmen: Prof. Yousr Gorgi).
[Ti] Título:Complement Component C3 Variant (R102G) and the Risk of Neovascular Age-Related Macular Degeneration in a Tunisian Population.
[Ti] Título:Komplementkomponente C3-Variante (R102G) und das Risiko für exsudative altersbedingte Makuladegeneration in der tunesischen Bevölkerung..
[So] Source:Klin Monbl Augenheilkd;234(4):478-482, 2017 Apr.
[Is] ISSN:1439-3999
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:To explore the association between the polymorphism (S/F) p.R102G in the C3 gene and age-related macular degeneration (AMD) in a Tunisian population. The molecular study was performed by polymerase chain reaction using sequence-specific primers (PCR-SSP) in 207 control subjects free of any eye disease (fundus normal) and 145 patients with exudative AMD. The activity and quantification of and have been made by technical home method and nephelometry, respectively. The prevalence of GG genotype polymorphism was significantly higher in AMD patients compared to controls (OR: 2.41, IC 95% [1.90-3.05], p = 0.0007). However, no correlation was found between this allelic variant and the type of neovascularization. Similarly, there is no association between this polymorphism and the presence of functional and/or quantitative hypocomplementemia. The GG genotype of the gene could be a susceptibility factor for AMD in the Tunisian population. However, it does not seem to influence the clinical profile of the disease.
[Mh] Termos MeSH primário: Complemento C3/genética
Estudos de Associação Genética
Predisposição Genética para Doença/epidemiologia
Predisposição Genética para Doença/genética
Degeneração Macular/epidemiologia
Degeneração Macular/genética
Polimorfismo de Nucleotídeo Único/genética
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Feminino
Marcadores Genéticos/genética
Seres Humanos
Incidência
Degeneração Macular/diagnóstico
Masculino
Meia-Idade
Mutação/genética
Reprodutibilidade dos Testes
Medição de Risco/métodos
Sensibilidade e Especificidade
Tunísia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (C3 protein, human); 0 (Complement C3); 0 (Genetic Markers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-104419


  7 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381911
[Au] Autor:Cheng J; Hao X; Zhang Z
[Ad] Endereço:Department of Ophthalmology, Aerospace Central Hospital, Beijing, China.
[Ti] Título:Risk of macular degeneration affected by polymorphisms in Matrix metalloproteinase-2: A case-control study in Chinese Han population.
[So] Source:Medicine (Baltimore);96(47):e8190, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to investigate the correlation of single nucleotide polymorphisms (SNPs) in Matrix metalloproteinase -2 (MMP-2) gene and the risk of age-related macular degeneration (AMD) in Chinese Han population.A total of 126 AMD patients and 141 healthy controls participated in this study. Genotypes of MMP-2 gene polymorphisms were identified by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). χtest was used to detect the differences of genotypes and alleles frequencies between case and control groups. Relative risk of AMD was evaluated by odds ratios (ORs) with 95% confidence intervals (CIs).Distribution of variant allele carriers (computed tomography + TT genotypes) of MMP-2 gene rs243865 SNP was significantly different between case and control groups, and might act as protective factors for the onset of AMD (P = .044, OR = 0.583, 95% CI = 0.344-0.987). Nevertheless, the T allele might reduce the AMD risk (P = .030, OR = 0.611, 95% CI = 0.390-0.956). However, no significant association existed between rs243865 and AMD risk in the subgroup analysis based on age. GA + AA genotypes of rs243866 SNP may associate with a decreased risk of AMD in the age≤65 years subgroup (P = .028, OR = 0.399, 95% CI = 0.174-0.915).MMP-2 gene rs243865 and rs243866 SNPs associated with the risk of AMD. Further studies should be performed to confirm the results.
[Mh] Termos MeSH primário: Degeneração Macular/epidemiologia
Metaloproteinase 2 da Matriz/genética
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Grupo com Ancestrais do Continente Asiático/genética
Estudos de Casos e Controles
China/epidemiologia
Feminino
Frequência do Gene
Genótipo
Seres Humanos
Degeneração Macular/genética
Masculino
Meia-Idade
Razão de Chances
Reação em Cadeia da Polimerase
Polimorfismo de Fragmento de Restrição
Polimorfismo de Nucleotídeo Único
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.24.24 (Matrix Metalloproteinase 2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008190


  8 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320624
[Au] Autor:Stojanov O
[Ti] Título:Charles Bonnet syndrome.
[So] Source:Vojnosanit Pregl;73(9):881-4, 2016 Sep.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Charles Bonnet syndrome (CBS) is a condition that causes visual hallucinations in patients without any mental illnesses. CBS is characterized by the presence of vivid, complex and recurrent visual hallucinations, and do not occur in the setting or as part of delirium or other psychological illnesses. The condition is present in patients who have visual loss due to age-related macular degeneration (AMD), cataracts and/or other ocular diseases that influence vision. Case report: A 81-year-od woman reported to ophthalmologist complaining of visual hallucinations that consisted of white pigeons. Hallucinations were present for two years and she was well aware that hallucinations were unreal. Mental illnesses were excluded by the psychiatrist. Complete ophthalmologic examination was performed, and finding revealed visual acuity of 0.3 (right eye) and 0.5 (left eye), in both eyes cataracts and AMD (wet form). Optical coherence tomography confirmed the fundoscopic finding of AMD. The patient rejected treatment of cataracts and AMD due to old age, and hallucinations persisted. Conclusion: CBS should be considered in patients with visual hallucinations and ocular diseases that influence vision. It is essential to distinguish CBS from mental illnesses, since patients with CBS are fully aware that hallucinations are not real. Awareness of CBS could help physicians upon referring patients to ophthalmologists instead of psychiatrists, and therefore avoid patients being misdiagnosed.
[Mh] Termos MeSH primário: Catarata/complicações
Síndrome de Charles Bonnet/etiologia
Degeneração Macular/complicações
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Catarata/diagnóstico
Catarata/fisiopatologia
Síndrome de Charles Bonnet/diagnóstico
Síndrome de Charles Bonnet/fisiopatologia
Síndrome de Charles Bonnet/psicologia
Diagnóstico Diferencial
Feminino
Seres Humanos
Degeneração Macular/diagnóstico
Degeneração Macular/fisiopatologia
Valor Preditivo dos Testes
Tomografia de Coerência Óptica
Recusa do Paciente ao Tratamento
Acuidade Visual
Percepção Visual
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150321140S


  9 / 13114 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778132
[Au] Autor:Karthikeyan B; Harini L; Krishnakumar V; Kannan VR; Sundar K; Kathiresan T
[Ad] Endereço:Department of Biotechnology, Kalasalingam University, Anand Nagar, Krishnankoil, Tamil Nadu, 626 126, India.
[Ti] Título:Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration.
[So] Source:Apoptosis;22(1):72-85, 2017 Jan.
[Is] ISSN:1573-675X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Endoplasmic reticulum (ER) stress-mediated apoptosis is a well-known factor in the pathogenesis of age-related macular degeneration (AMD). ER stress leads to accumulation of misfolded proteins, which in turn activates unfolded protein response (UPR) of the cell for its survival. The prolonged UPR of ER stress promotes cell death; however, the transition between adaptation and ER stress-induced apoptosis has not been clearly understood. Hence, the present study investigates the regulatory effect of (-)-epigallocatechin gallate (EGCG) on ER stress-induced by hydrogen peroxide (H O ) and disturbance of calcium homeostasis by thapsigargin (TG) in mouse retinal pigment epithelial (MRPE) cells. The oxidant molecules influenced MRPE cells showed an increased level of intracellular calcium [Ca ] in ER and transferred to mitochondria through ER-mitochondrial tether site then increased ROS production. EGCG restores [Ca ] homeostasis by decreasing ROS production through inhibition of prohibitin1 which regulate ER-mitochondrial tether site and inhibit apoptosis. Effect of EGCG on ER stress-mediated apoptosis was elucidated by exploring the UPR signalling pathways. EGCG downregulated GRP78, CHOP, PERK, ERO1α, IRE1α, cleaved PARP, cleaved caspase 3, caspase 12 and upregulated expression of calnexinin MRPE cells. In addition to this, inhibition of apoptosis by EGCG was also confirmed with expression of proteins Akt, PTEN and GSK3ß. MRPE cells with EGCG upregulates phosphorylation of Akt at ser473 and phospho ser380 of PTEN, but phosphorylation at ser9 of GSK3ß was inhibited. Further, constitutively active (myristoylated) CA-Akt transfected in MRPE cells had an increased Akt activity in EGCG influenced cells. These findings strongly suggest that antioxidant molecules inhibit cell death through the proper balancing of [Ca ] and ROS production in order to maintain UPR of ER in MRPE cells. Thus, modulation of UPR signalling may provide a potential target for the therapeutic approaches of AMD.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Catequina/análogos & derivados
Estresse do Retículo Endoplasmático/efeitos dos fármacos
Degeneração Macular/tratamento farmacológico
Resposta a Proteínas não Dobradas/genética
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Cálcio/metabolismo
Sinalização do Cálcio/genética
Catequina/administração & dosagem
Estresse do Retículo Endoplasmático/genética
Seres Humanos
Peróxido de Hidrogênio/toxicidade
Degeneração Macular/genética
Camundongos
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/genética
Estresse Oxidativo/efeitos dos fármacos
Espécies Reativas de Oxigênio/metabolismo
Tapsigargina/administração & dosagem
Resposta a Proteínas não Dobradas/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Reactive Oxygen Species); 67526-95-8 (Thapsigargin); 8R1V1STN48 (Catechin); BBX060AN9V (Hydrogen Peroxide); BQM438CTEL (epigallocatechin gallate); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s10495-016-1318-2


  10 / 13114 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777129
[Au] Autor:Coyle C; Cafferty FH; Rowley S; MacKenzie M; Berkman L; Gupta S; Pramesh CS; Gilbert D; Kynaston H; Cameron D; Wilson RH; Ring A; Langley RE; Add-Aspirin investigators
[Ad] Endereço:MRC Clinical Trials Unit, UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
[Ti] Título:ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
[So] Source:Contemp Clin Trials;51:56-64, 2016 11.
[Is] ISSN:1559-2030
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer therapy. METHODS: Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts. Patients who have undergone potentially curative treatment for breast (n=3100), colorectal (n=2600), gastro-oesophageal (n=2100) or prostate cancer (n=2120) are registered into four tumour specific cohorts. All cohorts recruit in the United Kingdom, with the breast and gastro-oesophageal cohort also recruiting in India. Eligible participants first undertake an active run-in period where 100mg aspirin is taken daily for approximately eight weeks. Participants who are able to adhere and tolerate aspirin then undergo a double-blind randomisation and are allocated in a 1:1:1 ratio to either 100mg aspirin, 300mg aspirin or a matched placebo to be taken daily for at least five years. Those participants ≥75years old are only randomised to 100mg aspirin or placebo due to increased toxicity risk. RESULTS: The primary outcome measures are invasive disease-free survival for the breast cohort, disease-free survival for the colorectal cohort, overall survival for the gastro-oesophageal cohort, and biochemical recurrence-free survival for the prostate cohort, with a co-primary outcome of overall survival across all cohorts. Secondary outcomes include adherence, toxicity including serious haemorrhage, cardiovascular events and some cohort specific measures. CONCLUSIONS: The Add-Aspirin trial investigates whether regular aspirin use after standard therapy prevents recurrence and prolongs survival in participants with four non-metastatic common solid tumours.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Aspirina/uso terapêutico
Recidiva Local de Neoplasia/epidemiologia
Neoplasias/tratamento farmacológico
Taxa de Sobrevida
[Mh] Termos MeSH secundário: Neoplasias da Mama/tratamento farmacológico
Quimioterapia Adjuvante
Neoplasias Colorretais/tratamento farmacológico
Intervalo Livre de Doença
Método Duplo-Cego
Hipersensibilidade a Drogas/etiologia
Neoplasias Esofágicas/tratamento farmacológico
Feminino
Hemorragia Gastrointestinal/induzido quimicamente
Seres Humanos
Índia/epidemiologia
Hemorragias Intracranianas/induzido quimicamente
Estudos Longitudinais
Degeneração Macular/induzido quimicamente
Masculino
Recidiva Local de Neoplasia/sangue
Úlcera Péptica/induzido quimicamente
Neoplasias da Próstata/sangue
Neoplasias da Próstata/tratamento farmacológico
Neoplasias Gástricas/tratamento farmacológico
Zumbido/induzido quimicamente
Reino Unido/epidemiologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161030
[St] Status:MEDLINE



página 1 de 1312 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde